Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report) CEO Chad M. Robins sold 117,351 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.98, for a total transaction of $819,109.98. Following the completion of the transaction, the chief executive officer now directly owns 2,814,350 shares of the company’s stock, valued at approximately $19,644,163. The trade was a 4.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Adaptive Biotechnologies Stock Down 5.4 %
Shares of NASDAQ ADPT opened at $7.35 on Friday. The firm’s 50-day moving average price is $7.55 and its two-hundred day moving average price is $6.02. Adaptive Biotechnologies Co. has a 52-week low of $2.28 and a 52-week high of $8.95. The stock has a market capitalization of $1.08 billion, a P/E ratio of -6.74 and a beta of 1.53.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. During the same period in the previous year, the company earned ($0.30) EPS. As a group, equities research analysts expect that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current year.
Hedge Funds Weigh In On Adaptive Biotechnologies
Wall Street Analyst Weigh In
Several brokerages have recently commented on ADPT. The Goldman Sachs Group increased their price target on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler reaffirmed an “overweight” rating and set a $11.00 price target (up previously from $7.00) on shares of Adaptive Biotechnologies in a research report on Thursday, February 20th. Finally, Scotiabank increased their price target on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.10.
Check Out Our Latest Analysis on Adaptive Biotechnologies
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Read More
- Five stocks we like better than Adaptive Biotechnologies
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Is Myers Industries Poised for a Breakout?
- Most Volatile Stocks, What Investors Need to Know
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.